Hikma Pharmaceuticals PLC (LON:HIK)
London
· Delayed Price · Currency is GBP · Price in GBX | Market Cap | 3.01B |
| Revenue (ttm) | 2.49B |
| Net Income (ttm) | 298.69M |
| Shares Out | 215.73M |
| EPS (ttm) | 1.34 |
| PE Ratio | 10.39 |
| Forward PE | 8.38 |
| Dividend | 0.62 (4.47%) |
| Ex-Dividend Date | Mar 19, 2026 |
| Volume | 61,304 |
| Average Volume | 802,893 |
| Open | 1,402.50 |
| Previous Close | 1,397.00 |
| Day's Range | 1,385.20 - 1,409.50 |
| 52-Week Range | 1,187.00 - 2,164.00 |
| Beta | 0.61 |
| RSI | 58.66 |
| Earnings Date | Aug 6, 2026 |
About Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The Hikma Rx segment offers oral, respiratory, and other generic and specialty products for the retail market. It provides i... [Read more]
Financial Performance
In 2025, Hikma Pharmaceuticals's revenue was $3.35 billion, an increase of 7.10% compared to the previous year's $3.13 billion. Earnings were $402.00 million, an increase of 11.98%.
Financial numbers in USD Financial StatementsNews
Hikma Pharmaceuticals Transcript: Trading update
Performance is in line with expectations, with robust demand and reiterated 2026 guidance. Strategic focus includes exiting the 503B business, investing in R&D, and expanding capacity. Middle East demand is strong, inflation is managed, and biosimilars lead in MENA.
UK's Hikma Pharmaceuticals reiterates 2026 outlook despite higher costs from Iran war
Hikma Pharmaceuticals reiterated its 2026 guidance on Thursday, adding that, while it has faced some pressure on shipping, energy, and insurance costs due to the war in the Middle East, a k...
Hikma Pharmaceuticals Earnings Call Transcript: H2 2025
CEO emphasized long-term growth, decentralization, and heavy R&D investment. Injectables face near-term margin pressure but are set for recovery post-2027, while Rx and MENA divisions drive current growth. $5B revenue target for 2030 remains on track.
Hikma Pharmaceuticals Earnings Call Transcript: H2 2025
Revenue grew 6% and core operating profit 3% in 2025, with strong Branded and Hikma Rx performance offsetting margin pressure in Injectables. 2026 guidance targets 2%-4% revenue growth, increased R&D spend, and margin stabilization, with over 250 product launches planned through 2029.
Hikma launches TYZAVAN™ (vancomycin injection, USP) in the US
Ready-to-use sepsis therapy marks new advancement in time-critical treatment LONDON , Dec. 8, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today an...
Hikma Pharmaceuticals Transcript: Trading Update
Guidance for 2024-2027 is revised to the lower end of revenue and EBIT growth ranges, with injectable margins now guided at 30% due to operational delays and higher R&D. Rx margins are set to approach 20% by 2026, supported by a strong pipeline and CMO growth.
Hikma Pharmaceuticals tumbles after injectables margin outlook cut
Shares of Hikma Pharmaceuticals fell as much as 10% on Thursday after a strong euro prompted the group to lower margin outlook for its injectables unit, despite beating expectations for overall interi...
Hikma Pharmaceuticals Earnings Call Transcript: H1 2025
Strong revenue growth across all segments, with injectables and branded divisions outperforming and robust R&D investment supporting future pipeline. Margins were impacted by FX and product mix, but guidance and long-term targets remain intact, with significant expansion in contract manufacturing and compounding expected.
Hikma Pharmaceuticals Earnings Call Transcript: H1 2025
Strong H1 2025 revenue growth was driven by new launches and the Xellia acquisition, though operating profit declined due to FX and mix effects. Full-year guidance is reiterated, with robust segmental performance and continued investment in capacity and R&D.
Hikma receives FDA approval for TYZAVAN™ (Vancomycin Injection, USP) in the US
Ready-to-infuse sepsis therapy marks new advancement in time-critical treatment LONDON , July 2, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today...
Hikma Pharmaceuticals USA announces $1 Billion of new US investment to further expand its domestic manufacturing and development of essential generic medicines
Next phase builds on 34+ years of serving the needs of US patients and healthcare providers COLUMBUS, Ohio , June 28, 2025 /PRNewswire/ -- In its ongoing mission to help meet America's growing need fo...
Bio-Thera Solutions and Hikma Pharmaceuticals Announce FDA Approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection
GUANGZHOU, China and LONDON , May 27, 2025 /PRNewswire/ -- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets...
Bio-Thera Solutions and Hikma Pharmaceuticals announce FDA approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection
GUANGZHOU, China and LONDON , May 27, 2025 /PRNewswire/ -- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets...
Hikma Pharmaceuticals Transcript: Trading update
Strong revenue growth and robust demand across all segments support reiterated 2025 guidance, with profit growth expected in the second half due to contract manufacturing timing. U.S.-based manufacturing and high inventory levels provide resilience against tariff and supply chain uncertainties, while ongoing investments in capacity and R&D underpin future growth.
Hikma acquires Novugen's FDA-approved ANDA for trametinib
LONDON , April 17, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces it has acquired the FDA-approved Abbreviated New Drug Application (...
Hikma Pharmaceuticals Earnings Call Transcript: H2 2024
FY24 results exceeded guidance, with double-digit growth in Injectables and Generics, and strong Branded performance. Strategic investments in R&D, capacity, and acquisitions like Xellia support a positive medium-term outlook, despite FX and pricing headwinds.
Hikma Pharmaceuticals Earnings Call Transcript: H2 2024
Core revenue grew 10% in 2024, exceeding guidance, with strong performance across all segments and significant investments in R&D and manufacturing. Outlook for 2025 anticipates continued growth, increased R&D spend, and margin stability despite some headwinds.
Hikma announces exclusive commercial partnership with Emergent BioSolutions for KLOXXADO® (naloxone HCl) nasal spray 8 mg
LONDON , Jan. 14, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical group, today announces that it has entered an exclusive commercial partnership with Emergent ...
Hikma Pharmaceuticals Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025
The event highlighted robust multi-year growth, strong margins, and a diversified business model across injectables, branded, and generics. Strategic investments in R&D, capacity, and acquisitions are driving expansion, with a focus on complex products and new market opportunities.
Hikma Pharmaceuticals Transcript: Investor Update
Ambitious growth in MENA is driven by a robust pipeline focused on chronic and specialty diseases, strong local manufacturing, and accelerated business development. Operational efficiency, stakeholder engagement, and strategic partnerships underpin margin expansion and market leadership.
Hikma Pharmaceuticals Transcript: Trading Update
Operating profit and revenue guidance are reiterated, with strong divisional performance and robust product pipelines. Contract manufacturing is set to expand significantly, supported by new deals and facility investments. R&D and branded business growth remain strategic priorities.
Hikma Pharmaceuticals participates in naloxone training event with U.S. Congressman Buddy Carter ahead of National Fentanyl Awareness and Prevention Day
LONDON, Aug. 20, 2024 /PRNewswire/ -- Hikma Pharmaceuticals in the US joined government officials and non-profit leaders today at a naloxone awareness and training event organized and hosted by Rep. E...
KLOXXADO® 8mg Naloxone Nasal Spray Shelf-Life Extended from 24 months to 36 months
LONDON , Aug. 15, 2024 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces the shelf-life extension of KLOXXADO® (naloxone HCl) nasal spray 8mg from ...
Hikma Pharmaceuticals Earnings Call Transcript: H1 2024
Delivered strong H1 results with 10% revenue growth and upgraded 2024 guidance. Injectables, Branded, and Generics all performed well, with significant investments in R&D, capacity, and M&A. Risks include increased competition and higher R&D costs in H2.
Hikma Pharmaceuticals Earnings Call Transcript: H1 2024
Group revenue grew 10% year-over-year, with strong branded and injectables performance and a flat core operating profit. Upgraded 2024 guidance projects 6%-8% revenue growth and $700-$730 million core operating profit, supported by robust cash flow and strategic investments.